FDA Gives Green Light to Clinical Trial of Zofin

FDA Gives Green Light to Clinical Trial of Zofin

285422

FDA Gives Green Light to Clinical Trial of Zofin

The U.S. Food and Drug Administration (FDA) has granted Organicell Regenerative Medicine permission to begin a clinical trial testing the company’s lead product, Zofin, in people with chronic obstructive pulmonary disease (COPD). The approved trial design will be a double-blinded, placebo-controlled, phase 1/2 trial to assess the safety and effectiveness of Zofin, delivered by intravenous (into-the-bloodstream) infusion, as a potential COPD treatment. “COPD is a chronic, degenerative, inflammatory lung disease with no current cure. We…

You must be logged in to read/download the full post.